Seshu Tyagarajan - 17 Mar 2025 Form 4/A - Amendment Insider Report for Candel Therapeutics, Inc. (CADL)

Signature
/s/ Charles Schoch, as Attorney-in-Fact for Seshu Tyagarajan
Issuer symbol
CADL
Transactions as of
17 Mar 2025
Net transactions value
-$250,147
Form type
4/A - Amendment
Filing time
20 Mar 2025, 16:35:16 UTC
Date Of Original Report
19 Mar 2025
Previous filing
14 Feb 2025
Next filing
26 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CADL Common Stock Options Exercise $25,800 +20,000 +21% $1.29 116,790 17 Mar 2025 Direct F1
transaction CADL Common Stock Sale $275,947 -31,278 -27% $8.82 85,512 17 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CADL Stock Option (Right to Buy) Options Exercise $0 -20,000 -22% $0.000000 70,000 17 Mar 2025 Common Stock 20,000 $1.29 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/15/2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.67 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.
F3 This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.

Remarks:

This amendment to the Form 4 originally filed on March 19, 2025 is being filed solely to include a transaction line in table I reflecting the acquisition of shares of Common Stock of the Issuer underlying stock options, which was inadvertently omitted in the original Form 4.